Rodman and Renshaw 18th Annual Global Investment Conference Date: Tuesday, September 13Time: 11:15am Eastern Time Location: The Lotte New York Palace Hotel Webcast: http://wsw.com/webcast/rrshq26/bcli
Maxim Inaugural Israel Day Date: Wednesday, September 14 Time: 11:00am Eastern Time Location: 405 Lexington Avenue, 2nd Floor
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
CONTACTS
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-ceo-to-present-at-two-investor-conferences-in-september-300322701.html
Contacts
Media:
Uri Yablonka, COO
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com
Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-ceo-to-present-at-two-investor-conferences-in-september-300322701.html